The OTCQB Venture Market offers early stage and developing companies the benefits of being publicly traded in the US and streamlined market standards which enable listed companies to provide a strong baseline of transparency to inform and engage with US investors.
To be eligible, companies must be current in their reporting, meet a minimum bid price test and undergo an annual verification and management certification process.
As a verified market with efficient access to US investors, OTCQB helps companies build shareholder value with a goal of enhancing liquidity and achieving fair valuation.
Artelo Biosciences is dedicated to the development and commercialization of proprietary endocannabinoid-modulating therapeutics designed to address significant unmet needs in multiple diseases and conditions, including cancer, pain, and inflammation.
RedHill Biopharma reports positive opaganib data in venetoclax-resistant CLL
InduPro secures strategic investment and collaboration with Sanofi to advance autoimmune therapy
Innovent Biologics reports first participant dosed in Phase 1 trial of IBI3011
LabGenius and Sanofi launch AI-driven collaboration on antibody optimisation
Sanofi and Regeneron's Dupixent approved in EU for chronic spontaneous urticaria
Xenogenic Materials Demonstrate Promising Results in Peri-Implantitis Management
European Commission approves Celltrion's Remsima IV liquid formulation
Biotheryx completes enrolment in ongoing Phase 1a trial of BTX-9341 for HR+/HER2- breast cancer